Skip to content
The Peptide Effect
Comparison

Tirzepatide vs Liraglutide

Tirzepatide (Mounjaro/Zepbound) and liraglutide (Saxenda/Victoza) are both FDA-approved for weight management, but they represent different generations of incretin therapy. Liraglutide was the first GLP-1 agonist approved for obesity (2014) and requires daily injections, producing ~8% weight loss. Tirzepatide is a dual GIP/GLP-1 agonist approved in 2023 that delivers nearly three times the weight loss (~22.5%) with once-weekly dosing. The generational leap in efficacy has made tirzepatide the preferred first-line option, though liraglutide remains relevant for pediatric use and patients who prefer starting with a milder, well-characterized agent.

Side-by-side comparison diagram of Tirzepatide and Liraglutide mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaTirzepatideLiraglutide
Primary mechanismDual GIP and GLP-1 receptor agonistSingle GLP-1 receptor agonist
Best forMaximum weight loss in adults, type 2 diabetes, patients wanting weekly dosingPediatric obesity (12+), patients wanting a well-established safety profile, milder initial approach
Route of administrationOnce-weekly subcutaneous injectionOnce-daily subcutaneous injection
Typical dosage2.5 mg escalating to 5 mg, 10 mg, or 15 mg weekly0.6 mg escalating to 3.0 mg daily (Saxenda for weight loss)
Average weight loss~22.5% at 72 weeks (SURMOUNT-1, 15 mg)~8.0% at 56 weeks (SCALE Obesity, 3.0 mg)
Half-life~5 days (once-weekly dosing)~13 hours (requires daily dosing)
Injection frequencyOnce weekly (4 injections/month)Once daily (30 injections/month)
FDA statusApproved: Zepbound (obesity, 2023), Mounjaro (T2D, 2022)Approved: Saxenda (obesity, 2014), Victoza (T2D, 2010)
Pediatric approvalNot yet approved for adolescentsApproved for adolescents 12+ (Saxenda, 2020)
A1C reduction~2.0–2.3% reduction~1.0–1.5% reduction
Side effectsNausea (31%), diarrhea (23%), vomiting (12%), constipation (11%)Nausea (39%), diarrhea (21%), vomiting (16%), constipation (19%)
Approximate monthly cost (US list price)$1,060–$1,200/month$1,350–$1,400/month (Saxenda)

When to Choose Each

Choose Tirzepatide

Adults seeking maximum weight loss with convenient once-weekly dosing, patients with type 2 diabetes needing aggressive A1C reduction, anyone who has tried liraglutide with insufficient results

Choose Liraglutide

Adolescents aged 12–17 with obesity, patients wanting the longest-established safety record in the GLP-1 class (15+ years), or those with limited insurance coverage for newer agents

Verdict

Tirzepatide is objectively superior to liraglutide in nearly every clinical metric — it produces almost three times the weight loss (22.5% vs 8%), better A1C reduction, and requires only weekly rather than daily injections. The convenience advantage alone makes tirzepatide the default first choice for most adults. Liraglutide still has a role for adolescents aged 12+ (where it has specific FDA approval), patients who prefer starting with a milder first-generation agent, or situations where tirzepatide is unavailable due to insurance or supply constraints. For most adult patients seeking meaningful weight loss, tirzepatide has effectively replaced liraglutide.

References

  1. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
  2. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes) (2015) — PubMed
  3. Liraglutide for weight management in pubertal adolescents with obesity (SCALE Teens) (2020) — PubMed
  4. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (2021) — PubMed

Frequently Asked Questions

Why would anyone choose liraglutide over tirzepatide?
There are several valid reasons: liraglutide is the only GLP-1 approved for adolescent obesity (ages 12+); it has the longest safety track record (approved since 2010); some insurance plans cover Saxenda but not Zepbound; and its shorter half-life means side effects resolve faster if they occur. Some clinicians also use low-dose liraglutide as a stepping stone before escalating to tirzepatide.
Can I switch from liraglutide to tirzepatide?
Yes, switching is common and straightforward. Most protocols stop liraglutide and start tirzepatide at the lowest dose (2.5 mg weekly) within a few days. Since liraglutide's half-life is only 13 hours, it clears your system within 2–3 days. Your prescribing physician can guide the exact transition timeline. Many patients experience additional weight loss after switching.
Is liraglutide being phased out?
Liraglutide is not being discontinued, but its market share has declined significantly since semaglutide and tirzepatide launched. Novo Nordisk still sells Saxenda (weight loss) and Victoza (T2D), and it remains important for pediatric obesity. However, for new adult prescriptions, semaglutide and tirzepatide have largely replaced it. Liraglutide may become more accessible as it approaches generic availability.
How long does it take to see weight loss results from tirzepatide vs liraglutide?
Research indicates that meaningful weight loss with both medications typically becomes noticeable within the first 4 to 8 weeks, though individual responses vary. In clinical trials, tirzepatide showed a steeper weight loss curve early on compared to liraglutide. Full results for either medication are generally observed after 6 to 12 months of consistent use at maintenance doses. Both require gradual dose escalation over several weeks to manage GI side effects, which delays reaching peak efficacy. A healthcare provider can help set realistic timeline expectations based on individual factors.
Are there differences in how tirzepatide and liraglutide are covered by insurance?
Insurance coverage varies significantly between the two. Liraglutide (Saxenda) has been on the market longer and may appear on more formularies, though coverage for weight loss medications remains inconsistent across plans. Tirzepatide (Zepbound) is newer and may face prior authorization requirements or step therapy mandates requiring patients to try other medications first. Costs without insurance are comparable at list price ($1,000–$1,400/month for both). Manufacturer savings programs, compounding pharmacy options, and employer-sponsored weight management programs may reduce out-of-pocket costs. Consulting with your insurance provider and prescribing physician is recommended to understand specific coverage options.

Explore next